Celebrating 15 Years of Advancing Biopharma Collaboration

The approval of new therapies increasingly relies on an ecosystem of strategic partnerships during various stages of the development pipeline. Successfully managing these partnerships has become a critical component to the underlying success of each partner and the biopharma industry. As the quantity and complexity of deals increase, alliance teams have rapidly evolved, developing innovative strategies, systematic approaches and best practices to maximize value, and to leverage strategic partnerships above and beyond the deal.

Cambridge Healthtech Institute’s 15th Annual Strategic Alliance Management Congress, May 7-9, brings together senior alliance management, business development, technology transfer and licensing professionals to network, discuss case studies, and share the components that cultivate successful partnerships. Delegates will gain strategic insights, proven tools, methods, and perspectives from a variety of leaders advancing the art of alliance management.


Keynote Speakers

 


Simon Bateman, PhD
Executive Director, Global Strategic Alliance Management, Novartis Oncology
 
Dana Hammill, MS, MBA
Director, Business Development and Alliances, Center for Cellular Immunotherapies, University of Pennsylvania
 
Stuart Kliman, JD
Partner, Vantage Partners
 

Agenda At-A-Glance



  • Opening Icebreaker with Pfizer
  • Installing Alliance Management Function and Building Capability with Shire and Eisai
  • Developing Alliance Capability and Culture with Bayer HealthCare and The Rhythm of Business
  • Managing Technology-Based Partnerships with Amblyotech and Vantage Partners
  • Partners of Choice: A Look into Pfizer, Bayer, Sanofi, GlaxoSmithKline, AbbVie, AstraZeneca, Merck, Celgene and Boehringer Ingelheim
  • Case Studies of Ongoing Partnerships and Alliance Management with University of Pennsylvania, Novartis Oncology, Aralez Pharmaceuticals and AstraZeneca
  • Managing Academic, Manufacturing and Patient Advocacy Partnerships with Mount Sinai Health System, Sanofi, IDT Biologika and Retrophin